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Abstract
Objective: To develop and validate a clinical risk prediction score for noninvasive ventilation (NIV) failure defined as
intubation after a trial of NIV in non-surgical patients.
Design: Retrospective cohort study of a multihospital electronic health record database.
Patients: Non-surgical adult patients receiving NIV as the first method of ventilation within two days of
hospitalization.
Measurement: Primary outcome was intubation after a trial of NIV. We used a non-random split of the cohort based
on year of admission for model development and validation. We included subjects admitted in years 2010–2014 to
develop a risk prediction model and built a parsimonious risk scoring model using multivariable logistic regression.
We validated the model in the cohort of subjects hospitalized in 2015 and 2016.
Main results: Of all the 47,749 patients started on NIV, 11.7% were intubated. Compared with NIV success, those who
were intubated had worse mortality (25.2% vs. 8.9%). Strongest independent predictors for intubation were organ
failure, principal diagnosis group (substance abuse/psychosis, neurological conditions, pneumonia, and sepsis), use
of invasive ventilation in the prior year, low body mass index, and tachypnea. The c-statistic was 0.81, 0.80 and 0.81
respectively, in the derivation, validation and full cohorts. We constructed three risk categories of the scoring system
built on the full cohort; the median and interquartile range of risk of intubation was: 2.3% [1.9%–2.8%] for low risk
group; 9.3% [6.3%–13.5%] for intermediate risk category; and 35.7% [31.0%–45.8%] for high risk category.
Conclusions: In patients started on NIV, we found that in addition to factors known to be associated with intubation,
neurological, substance abuse, or psychiatric diagnoses were highly predictive for intubation. The prognostic score
that we have developed may provide quantitative guidance for decision-making in patients who are started on NIV.
Keywords: Intubation, noninvasive ventilation failure, Predictive score, Acute respiratory failure, Mechanical
ventilation
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Introduction
Noninvasive ventilation (NIV) plays a key role in the
treatment of acute respiratory failure (ARF) and its use
is supported by multiple randomized controlled trials
[1–4]. The evidence of benefit is strong for patients with
acute hypercapnic respiratory failure [1, 5] and cardiogenic pulmonary edema [6, 7], while consistent benefit
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in other conditions such as acute hypoxemic respiratory
failure was not found [8–10]. Even so, the use of NIV
has dramatically increased in the last two decades in the
US for all diagnoses regardless of supporting evidence
[11–14].
Therapy with NIV is considered successful if endotracheal intubation is avoided. Conversely, the term NIV
failure is used when a patient initially treated with NIV
requires invasive mechanical ventilation (IMV) or dies
without being intubated. NIV failure rates range from 5
to 50% and patients who are intubated have an increased
risk of death compared to those treated with IMV from
the outset [9, 11, 15–17]. Determining which patients are
appropriate for NIV therapy is a complex decision that
requires assessment of an individual’s chances of failure
and/or survival; improper patient selection is a main
reason for poor outcomes [18–20]. Prior studies have
identified several risk factors associated with NIV failure
including coexistent pneumonia, tachypnea, hypotension, severe acidemia, higher severity of illness score, or
failure to improve in one hour. However, most of these
studies were small, were developed in cohorts from randomized trials, or were geared towards specific diagnoses
[15, 21–24].
A simple risk score developed in a real-world cohort
to identify patients’ risk for NIV failure may support
clinical decision for initiation of NIV and trigger goals
of care discussions at the time of NIV initiation. It may
also help with decisions regarding monitoring; patients at
low risk of failure could be potentially admitted in a stepdown unit, whereas those at high risk could benefit from
admission to an intensive care unit. Therefore, using data
from a large multihospital electronic health record database that contains vitals and laboratory results, we sought
to develop a clinical risk score for NIV failure defined as
intubation after a trial of NIV based on information routinely available to clinicians at the time of NIV initiation.

patients transferred to or from another facility. We used
ICD-9 CM and ICD-10 CM procedure codes to identify
NIV treatment; prior studies have shown that these procedure codes have sensitivity of 86.5% and specificity of
91.5% [25].

Materials and methods

The primary outcome was intubation following a trial of
NIV.
Our secondary outcome was NIV failure defined as
intubation or death.

Design, data source, and population

We conducted a retrospective cohort study using an electronic health record dataset, Cerner HealthFacts from
January 2010 to July 2016. Health Facts contains data on
patient demographics, diagnoses and procedures and
detailed, time-stamped, clinical, pharmacy and laboratory results. For this analysis, we included 127 hospitals that contributed data to all domains (laboratory,
pharmacy, vitals, and administrative data). We included
non-surgical patients 18 years or older with NIV initiated in the first two days of hospitalization. We excluded
patients receiving palliative care or hospice, patients with
obstructive sleep apnea (we could not ascertain if NIV
was used for OSA or for acute respiratory failure), and

Candidate risk factors

Potential candidate variables were identified based on a
review of the literature and clinical relevance [15, 16, 21–
24]. Patients were grouped into the following 11 major
categories based on the evidence for NIV use and size of
the cohort: (1) congestive heart failure (CHF), (2) acute
myocardial infarction (AMI) (3) chronic obstructive pulmonary disease (COPD), (4) asthma, (5) pneumonia, (6)
sepsis, (7) stroke, (8) neurological non-stroke diagnosis,
(9) substance abuse, (10) psychiatric diagnoses, (11) others. To assess severity of illness we used the following variables: number of hospitalizations and NIV or IMV use
in the year prior to the index admission; vasopressor use
within first two days of hospitalization and organ failure
(acute respiratory failure was not counted) [26, 27]. We
also included the following comorbidities known to be
associated with NIV failure: chronic pulmonary disease,
neurological disorders, psychiatric disorders, substance
abuse, obesity, and weight loss. Vitals and laboratory
variables known to be predictive for NIV failure such as
respiratory rate, heart rate, blood pressure or bicarbonate
were grouped into categories based on the Laboratory
Acute Physiology Score (LAPS), which uses the results of
laboratory testing around the time of admission to quantify the risk of inpatient mortality [28, 29]. For example,
respiratory rate in our model was categorized as ≤ 29versus ≥ 30 with points assigned for patients with high respiratory rate [28]. We grouped missing values as separate
category for factors that contained them and included in
all analyses.
Outcomes

Statistical analysis

We computed summary statistics to characterize the
cohort and calculated standardized mean differences to
compare groups with and without the outcome of interest; a difference of > 10% is deemed significant [30].
Derivation and validation data sets: we split the cohort
non-randomly based on year of admission with patients
admitted in years 2010–2014 for model derivation and
patients admitted in years 2015–2016 for validation. We
first computed Spearman’s rank correlations between
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factors to check for any collinearity between predictors
We developed a series of multivariable logistic regression
models to predict intubation in the derivation cohort. We
initially included all the candidate risk factors, and then
removed those that did not add significantly to the model
[31]. We used a backward selection process wherein we
selected factors based on their contribution to the model
via Type 3 sums of squares. Further, to increase the likelihood that the model will be used in real-time for risk
stratification purpose, we reduced the number of variables: first, we selected those with the strongest predictive
ability; second, we combined candidate factors that were
clinically comparable and had a similar magnitude of
effect. Factors that had greater contribution to the model
were selected with a cut-off at the top 10 variables. The
final model was fit and checked for model performance
using the c-statistics and compared it against the full
model performance. Discrimination was evaluated by the
area under the receiver operating characteristic (ROC)
curve [32] and calibration was measured by review of
the calibration plots. Parameter estimates obtained from
the derivation cohort were then used to compute individual intubation risk in the validation cohort of patients
admitted in year 2015 and 2016. Models were assessed
for possible overfitting using the least absolute shrinkage
and selection operator (LASSO) method [33]. To assess
the robustness of the model we used a fivefold crossvalidation technique [34]. We divided the full cohort
into 5 segments (“folds”) and then refit the model that
we developed in the derivation cohort in 4 of the “folds”
(80% data) and validated it on the remaining fold (20%
data). This was performed a total of 5 times, leaving out
a different “fold” each time; we then computed c-statistics as a measure of assessment of model fit for each
validation “fold”. Finally, we fit the model in full cohort
and then developed a point-scoring system for intubation using a regression coefficient-based scoring method
[35]. The total risk score was calculated by adding each
component, and intubation rates were determined for
the various scores. We then computed the probability of
intubation at different cut-points for the total score and
constructed 3 categories of intubation risk (low, medium
and high). We employed similar a analytic strategy for the
NIV failure outcome defined as intubation or death.
All analyses were conducted using SAS statistical software (Version 9.4; SAS Institute Inc, Cary, NC) and Stata
statistical software (Version 15; STATA Corp, College
Station, Texas).
The study has been performed in accordance with the
Declaration of Helsinki and has been approved by the
Baystate Institutional Review Board. Informed consent
was not required as this was a retrospective study of deidentified data.
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Results
There were 94,744 hospitalizations of non-surgical
patients with NIV initiated within the first 2 days of
admission at 127 hospitals. After exclusion criteria
were applied (Fig. 1), our full cohort consisted of 47,749
patients.
Cohort characteristics

47,749 patients were included in our analysis; median
age was of 65 years, 48.2% were female and 74.8% were
of white race. The most common principal diagnoses were sepsis or pneumonia (23.5%), AMI (22.7%),
and COPD/asthma (17.5%); 40% of patients had one
or more prior admissions and 11.5% had received NIV
in the prior year. About thirty-seven percent of the
patients had one or more organ failures (in addition to
acute respiratory failure), 16.4% were treated with vasopressors. Among the 43,277 patients initiated on NIV
by day 1, 75.5% were started in the emergency department. Summary statistics of demographics, comorbidities, and presenting features are shown in Additional
file 1: Table E1. In-hospital mortality was 10.8% and the
median length of stay was 5 days (IQR: 3–9). Overall,
5,572 (11.7%) patients were intubated and 1,402 (25.2%)
of those who intubated died.
Characteristics of patients who were intubated

Compared to patients who were not intubated, patients
who were intubated were younger (median age 62
vs. 66 years), more likely to be of Black race (22.0% vs.
15.4%), and more likely to have been treated with IMV
in the prior year (6.8% vs. 2.7%). Those who were intuabted were sicker, with higher rates of comorbidities
including neurological disorders (21.8% vs. 9.8%), liver
disease (7.3% vs. 3.1%), and psychiatric disorders (20.4%
vs. 11.8%); they had higher use of vasopressors (25.0%
vs. 16.6%); were more likely to have one or more organ
failures (67.3% vs. 29.5%) or comorbid pneumonia (33.0%
vs. 20.0%); and higher admission LAPS score (median
score 50 vs. 40) (Additional file 1: Table E1). Compared with those in whom NIV was successful, those
who were intubated had higher mortality (25.2% vs.
8.9%; p-value < 0.001) and longer length of hospital stay
[median (IQR): 8 (3–16) vs. 5 (2–8); p-value < 0.001].
Rates of intubation or death after intubation varied
dramatically by condition; for example, patients with
substance abuse or a psychiatric diagnosis had the highest intubationrate of 29.3% but a low mortality after intubation of 7.3%, while patients with AMI had the lowest
intubation rate of 3.9% but a high mortality among those
intubated of 34.2%; patients with stroke had both high
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Table 1 Rates of overall death, intubation, no intubation, death with and without intubation in patients treated
with noninvasive ventilation
Diagnosis

Entire cohort

Death overall Intubation Death after intubation No. intubation Death
p-value*
without intubation

N (column %) Row %
Total number of patients

5,150 (10.8)

Row %

5,572 (11.7) 1,402 (25.2)

Row %

Row %

42,177 (88.3)

3,748 (8.9)

COPD/ASTHMA

8346 (17.5)

470 (5.6)

941 (11.3)

155 (16.5)

7405 (88.7)

315 (4.3)

< 0.001

CHF

4896 (10.3)

336 (6.9)

351 (7.2)

90 (25.6)

4545 (92.8)

246 (5.4)

< 0.001

AMI

10,820 (22.7)

663 (6.1)

424 (3.9)

145 (34.2)

10,396 (96.1)

518 (5.0)

< 0.001

Pneumonia/sepsis

11,219 (23.5)

2331 (20.8)

2028 (18.1)

686 (33.8)

9191 (81.9)

1645 (17.9)

< 0.001

Neuro non-stroke

1672 (3.5)

85 (5.1)

304 (18.2)

20 (6.6)

1368 (81.8)

65 (4.8)

0.19

Stroke

1832 (3.8)

597 (32.6)

384 (21.0)

137 (35.7)

1448 (79.0)

460 (31.8)

0.15

Substance abuse/psychosis

2469 (5.2)

153 (6.2)

723 (29.3)

53 (7.3)

1746 (70.7)

100 (5.7)

0.13

Other diagnoses

6495 (13.6)

515 (7.9)

417 (6.4)

116 (27.8)

6078 (93.6)

399 (6.6)

< 0.001

*

47,749 (100)

Row %

Chi-square test testing for association between death after intubation and death without intubation within each principal diagnosis group

intubation rate (21.0%) and mortality after intubation
(35.7%). (Table 1).
Predictors of intubation

When we assessed for collinearity, due to our large sample size, though we saw statistically significant results
between some factors, the correlations were small and
not meaningful. Among the 31,053 patients in derivation
cohort, the strongest predictors for intubation were presence of additional organ failure (in addition to acute respiratory failure) and principal diagnosis groups. A final
model was built in full cohort including these selected
10 factors. Compared to the referent group with principal diagnosis of AMI, patients with stroke had about 6.2
times higher odds of NIV failure and those with a nonstroke neurological conditions, 5.4 times higher odds of
intubation. Patients with two or more organ failures in
addition to ARF at the time of admission had 5.3 times
higher odds of intubation compared to those without additional organ failure. Also, the following factors
increased the odds of intubation: prior year IMV use by
a factor of 3.0, pneumonia as a comorbid condition with
an odds ratio of 2.2, and tachypnea with an odds ratio of
1.9. The model performed well with a c-statistic of 0.81.
The main predictors of intubation and the scoring system
from the associated model coefficients from full cohort
are presented in Table 2.
Model validation

Characteristics of patients in derivation and validation
cohorts are in Additional file 1: Table E2. We observed
that compared with the derivation cohort, the validation cohort patients were less likely to be Black, more
likely to have AMI, and less likely to have hypercarbia;

there were no significant differences in the outcome
rate. When the intubation simplified score was applied
to the validation set, the c-statistic was 0.80. Predicted
and observed intubation rates in the validation cohort
were in close agreement except in the highest deciles
(Additional file 1: Figure E1 in online data supplement).
C-statistics from the fivefold validation showed good
discrimination with values of 0.80 or greater across the
fivefolds showing robustness of the final model.
Risk score

Ten variables were included in the final risk score:
organ failure, principal diagnosis, secondary diagnosis of pneumonia or weight loss, requiring IMV in the
prior year, low BMI, presence of tachypnea, presence of
hypotension, low bicarbonate, and not having admissions in prior year. A patient who falls into each of the
scored variable category can have a maximum score
of 38 with a risk of intubation of about 97.9%. Patients
who were intubated had a significantly higher risk score
(median: 14, IQR: 10–17) than patients who were not
intubated (median: 7, IQR: 3–10). The median, interquartile range and overall range of risk of intubation in
the 3 risk categories of the scoring system were: 2.3%
(IQR: 1.9%–2.8%; range: < 4.0%) for the low risk category (score ≤ 5); 9.3% (IQR: 6.3%–13.5%; range: 4.0%—
23%) for intermediate risk category (score 6–14); and
35.7% (IQR: 31.0%–45.8%; range: > 23%) for high risk
category (score ≥ 15) (Fig. 2).
Table 3 shows the predictors and the risk score for
NIV failure defined as intubation or death. Although
the points for individual factors changed, the same variables were included.
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Table 2 Predictors for intubation in derivation and full cohorts
Factor

Derivation cohort

Full cohort

Odds ratio (95% CI)

Odds ratio (95% CI)

None

Referent

Referent

One

2.29 (2.08, 2.53)

2.37 (2.19, 2.56)

4

Two or more

5.46 (4.95, 6.02)

5.34 (4.94, 5.78)

8

Acute myocardial infarct

Referent

Referent

COPD/asthma

3.24 (2.77, 3.80)

2.94 (2.59, 3.34)

5

Congestive heart failure

1.80 (1.49, 2.17)

1.52 (1.30, 1.78)

2

Pneumonia or Sepsis

3.94 (3.40, 4.56)

3.54 (3.15, 3.98)

6

Neuro non-stroke

5.53 (4.55, 6.72)

5.35 (4.56, 6.32)

8

Stroke

6.84 (5.62, 8.33)

6.18 (5.28, 7.24)

8

Substance abuse or psychosis

10.09 (8.47, 12.01)

8.70 (7.58, 9.99)

10

Other

1.78 (1.49, 2.14)

1.54 (1.33, 1.77)

2

Pneumonia (secondary dgn)

2.27 (2.04, 2.53)

2.21 (2.02, 2.42)

4

Prior year invasive mechanical vent

2.98 (2.51, 3.53)

3.05 (2.65, 3.51)

5

Points

Number of organs failed

Primary diagnostic group

Systolic blood pressure
≥ 91

Referent

Referent

≤ 90

1.55 (1.42, 1.68)

1.51 (1.42, 1.62)

18.0—25.0

Referent

Referent

< 18.5

1.18 (1.02, 1.36)

1.23 (1.10, 1.39)

22 – 27

Referent

Referent

< 22

0.96 (0.88, 1.04)

1.02 (0.96, 1.10)

1

Weight loss (secondary dgn)

1.51 (1.35, 1.68)

1.48 (1.35, 1.62)

2

No prior year admissions

1.42 (1.31, 1.55)

1.41 (1.32, 1.51)

2

Referent

Referent

1.75 (1.33, 2.30)

1.92 (1.53, 2.40)

2

Body mass index
1

Bicarbonate

Respiratory rate
≤ 29

≥ 30

3

For physiological variables we chose the worst value in the 24 h prior to NIV initiation

Discussion
Using a large cohort of non-surgical patients treated
with NIV at 127 US hospitals, we found that a simple
model using data available at hospital presentation
successfully predicted intubation after initial treatment with NIV. The final risk score includes number
of organ failure, principal diagnosis, acute physiological parameters, and chronic disease comorbidities, and
provides a simple method to stratify a patient’s risk of
NIV failure into low and high risk categories relative to
an intermediate group at average risk. Because of the
large size of our cohort and the large network of hospitals contributing data, our model is statistically robust
and highly generalizable. This model has significant
potential for being incorporated in an online prognostic calculator (see example Additional file 1: figure E2

in the supplement) to help routine decision-making by
providers and support appropriate monitoring and/or
counseling of patients and families. We have also developed a risk score for NIV failure defined as intubation
or death which included the same factors as the intubation only model, although the weight of the predictors changed slightly. Of note, our risk score applies to
patients started on NIV soon after admission and not
to patients who develop respiratory distress and are
treated with NIV later in the course of hospitalization.
The present model differs from prior models used to
predict intubation in patients started on NIV in several
ways [15, 21–24]. First, our model was designed to be
used in any non-surgical patient started on NIV, regardless of the principal diagnosis, allowing for broader utility. Therefore, our study was not restricted to specific
conditions such as COPD or CHF where the evidence
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Table 3 Predictors for noninvasive ventilation failure
(intubation or death)
Factor

Intubation or death
OR

LL

Score

UL

Number of organs failed
None

Referent

One

1.646

1.543

1.755 2

Two or more

3.733

3.501

3.981 6

Primary diagnostic group
Acute myocardial infarct

Referent

COPD/asthma

1.804

1.634

1.991 3

Congestive heart failure

1.275

1.135

1.433 1

Pneumonia or sepsis

3.464

3.181

3.771 5

Neuro non-stroke

2.79

2.423

3.213 5

Stroke

9.664

8.565 10.903 10

Substance abuse or psychosis

4.293

3.828

4.815 6

Other

1.343

1.21

1.491 1

Pneumonia (secondary dgn)

1.966

1.818

2.127 3

Prior year invasive mechanical vent 1.913

1.682

2.176 3

1.959

2.187 3

1.241

1.517 2

Systolic blood pressure
≥ 91

Referent

≤ 90

2.07

18.0–25.0

Referent

< 18.5

1.372

Body mass index

Bicarbonate
22 – 27

Referent

< 22

0.737

0.697

0.779 1

Weight loss (secondary dgn)

1.19

1.097

1.291 1

2.064

3.044 4

Respiratory rate
≤ 29

≥ 30

Referent
2.507

c-stat: 0.78

For physiological variables we chose the worst value in the 24 h prior to NIV
initiation

for use of NIV is strong. Instead, we developed our
predictive model in a large group of patients treated
with NIV in routine clinical settings. Several predictive
scores exist for specific diagnoses. For example, Confalonieri and colleagues developed a prediction chart
of failure risk in patients with COPD [22]. They found
that patients with an APACHE II score ≥ 29, a Glasgow
coma score < 11, and a respiratory rate ≥ 30 breaths/min
have a predicted risk of NIV failure of > 70%. However,
inclusion of the APACHE II score makes it less practical
due to the multiple variables needed, including laboratory tests. Second, our approach is novel in that is using
a large EHR dataset. The variables in our model are
easily obtainable and the scoring could be applicable

not only for clinical purposes but also for studies with
administrative data. Third, we have developed a tool
to quantitatively estimate the risk for intubation. If the
risk is high, clinicians have to make the difficult decision between NIV and IMV given that those who fail
NIV have mortality which is similar or even higher than
those started on IMV [9, 16]. Prior studies have shown
that at least part of the increase in mortality is related
to delayed intubation; this is why, if NIV is started in
patients at high risk for failure, these patients need to
be closely watched in a highly monitored environment.
In this study we found that when NIV was started for
unusual diagnoses such as drug overdose or seizure, the
risk of NIV failure was high; for this group, the decision to intubate has to be seriously considered. Fourth,
the prognostic model can be used as an aid in making
decisions about placement of patients in ICU or intermediate care, thereby matching the intensity of monitoring with the needs of the patient [36, 37]. Of note,
in a step-down unit, patients are generally monitored
with the same technology as in an ICU but frequency
of monitoring and the intensity of care provided by
the nurses and respiratory therapists is lower [38, 39].
Currently, there is large variation in policies regarding administration of NIV across hospitals, with some
institutions restricting NIV utilization to the ICU while
others allow it on step-down units [20, 37]. Our scoring system can help tailor these decisions. For example,
patients with substance abuse, pneumonia, renal failure
(one organ dysfunction), cachexia, a prior year intubation, and tachypnea will have a total score of 28, giving them an 85% probability for NIV failure (Additional
file 1: Figure E2); consequently, these patients should
be closely watched in the ICU or intubated in the first
place.
Our results largely confirm a number of risk factors
for NIV failure that have been previously described by
other studies [9, 11, 15, 17]. However, a surprising finding
of our study is the large number of patients treated with
NIV who had neurological, substance abuse, or psychiatric diagnoses; most of which are not typical for acute
respiratory patients. Notably, only 35.3% of the 5,973
patients with these diagnoses had a secondary diagnosis of conditions that would suggest an indication for
NIV such as CHF, asthma, COPD, AMI, pneumonia or
sepsis, raising questions on the purpose of using NIV in
this cohort. Furthermore, this group had a higher risk for
intubation compared with patients with CHF or COPD:
almost one in three patients in this category needed to be
intubated after a trial of NIV, demonstrating that they are
not good candidates for NIV. We are not able to identify
the reason why these patients were started on NIV. One
could hypothesize that these patients became lethargic
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Fig. 1 Patient selection flow chart

Fig. 2 Risk score categories and associated probability of intubation

and hypo-ventilated due to their primary diagnosis and
consequently became hypoxic or hypercarbic, triggering
the use of NIV. While it is true that these are not standard indications for NIV, our data reflect routine care in a
large unselected population.
Organ failure was a strong predictor for intubation or
NIV failure and patients with two or more organ failures
were five times more likely to experience failure than
those without organ failure. Although there is strong evidence that organ failure is an important risk factor for
intubation or NIV failure, in this real-world cohort 35%
of patients treated with NIV and 62% of those who failed

NIV had at least one organ failure. This scoring system
could help providers to be more vigilant when choosing
to deliver NIV to a patient with relative contraindications
for NIV.
The results of our study should be interpreted considering its limitations. First, we did not have data on clinical assessments at the 1–2 h time point after initiation
of NIV, findings that have been shown to predict NIV
success [24]. Nevertheless, our model was intended to
provide prognostic information at the time of NIV initiation. Evaluating the response to the NIV is a key aspect of
management. However, once the follow-up assessment is
made with our risk score, one can adjust the initial prediction (aka ‘prior probability’) based on the new information. Second, our outcome was NIV intubation and
did not take in account the competing risk of death (8.9%
of patients died without being intubated). For this reason,
we have also developed a predictive score for intubation
or death. Third, we relied on ICD-9CM and ICD-10CM
diagnostic codes which could have resulted in misclassification. Fourth, we lacked information on advance
directive status and therefore patients with a do-not-intubate status could have been retained in the cohort. Fifth
although the prediction model was validated via a temporal external cohort, future validation in another cohort
including additional sites is needed. Sixth, we did not
have information about the use of high flow nasal oxygen
in this population. Finally, this model does not apply to
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surgical patients or those with OSA who were excluded
from the cohort.

Conclusions
Clinical variables at the time of admission can be used to
accurately predict the risk of intubation and of intubation
or death, in a broad sample of hospitalized patients using
readily available clinical data. The prognostic score may
provide quantitative guidance for decision-making about
patients with acute respiratory failure who may require
conventional mechanical ventilation. Although multiple risk scores for intubation or NIV failure exist few are
utilized in routine care. Our score which is applicable to
any adult patient for whom a provider is considering NIV
could be built in a web-based calculator for easy use at
the point-of-care.
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